

Biomarker-guided clinical trials for rare and very rare cancers

Horizon Europe

Generated at: October 8, 2026

● PENDING

Code

HORIZON-MISS-2027-02-CANCER-03

Scope

International

Location

Europe

Curator

Marlene Faria

Financial Details

Support type

Non-Refundable

Maximum Funding Rate

100%

Budget

24M€

Eligible Project Value

7M€ - 9M€

Dates & Deadlines

Publication Date

October 5, 2026

Opening Date

February 10, 2027

Fase única

September 16, 2027 at 05:00 PM GMT+2

Description

Objectives

The main goal of this incentive is to advance biomarker-guided medicines and multi-modal treatment interventions specifically tailored for patients with rare and very rare cancers. The target group includes patients, researchers, physicians, innovators, startups, SMEs, charities, healthcare providers, and policymakers across EU Member States and Associated Countries. The aim is to enable access to early-stage trials, innovative technologies, and validated interventions that have the potential to significantly improve overall survival rates and expand therapeutic options where few exist today.

Funding

Funding is provided under a Horizon Europe Research and Innovation Action (RIA) within the framework of the EU Mission on Cancer. The topic has an indicative budget of €24 million, with the European Commission expecting to fund three projects. The expected EU contribution ranges between €7 million

and €9 million per project, although proposals requesting different amounts may be considered where adequately justified.

Eligible Expenses

- Personnel Costs
- Travel costs
- Equipment costs
- Other goods, works and services costs
- Subcontracting
- Indirect Costs
- Preclinical research
- Clinical trial costs
- Networking and meetings
- Stakeholder engagement
- Data management
- Regulatory consultation costs
- Open data infrastructure
- Patient and caregiver involvement activities

Bonuses & Majorations

- Participation in EU Cancer Mission 'Diagnosis and treatment' cluster
- Collaboration with Knowledge Centre on Cancer resources

Eligibility

Eligible Sectors

Health & Life Sciences

Application Mode

Consortium / Copromotion

Company Typologies

- SME
- Large
- Private non-profit entities
- Public entities

Action Types

- Preclinical validation
- Clinical trials
- Innovative medicine validation
- Biomarker-guided drug development

- Patient engagement
- Open science data management
- Stakeholder coordination
- Research and Innovation Actions

EU Programme Details

Call ID

HORIZON-MISS-2027-02-CANCER-03

Cluster

Mission

Destination

Cancer

Submission Mode

Single-stage

EU Contribution

Around €7,000,000.00 to €9,000,000.00 per project

Expected Projects

3

Funding Rate Rule

Up to 100% of eligible costs for Research and Innovation Actions (RIA)

Official Links

Official Regulation

<https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/HORIZON-MISS-2027-02-CANCER-03?order=DESC&pageNumber=1&pageSize=50&sortBy=startDate&keywords=HORIZON-MISS-2027-02-CANCER-03&isExactMatch=true&status=31094501,31094502,31094503>

Grantavia page

<https://grantavia.com/en/incentives/biomarker-guided-clinical-trials-for-rare-and-very-rare-cancers>

Schedule a meeting

<https://calendly.com/sandra-cardoso-epsa/reuniao>